03/06/2022 16:38

Healius (HLS) $3.80

HLS -8.17%: the medical centre and pathology operator struggled today after a poor trading update.  Medicare data has shown both pathology and imaging have fallen more than 8% in the four months to April, and while Healius is said to be tracking at better levels, the fall has weighed on earnings. COVID testing has also fallen dramatically, now running at 15,000 tests per working day as RATs become the go-to method. Staff infections...

Read more

12/05/2022 09:36

Healius Ltd (HLS) $4.01

HLS has now corrected over 30% from its late December high after falling another -4.5% yesterday following Credit Suisse cutting the health care business to neutral albeit with a price target of $4.65. In late February the business delivered a strong half-year result although the likelihood moving forward is the tailwind demand for PCR testing will fall away – we hope so! However, we anticipate HLS will enjoy an acceleration...

Read more

08/02/2022 09:11

Healius Ltd (HLS) $4.48

HLS has corrected 22% from its 2022 high as sentiment towards growth stocks has deteriorated on rising inflation – the same old story. However HLS has also encountered extra selling as the demand for COVID testing has fallen away as more people and importantly the government become comfortable with RATs. We feel this selling pressure is likely to...

Read more

16/12/2021 09:42

Healius (HLS) $5.03

HLS has been a great performer over the last few years and we believe the trends your friend here with a test of $5.50 looking likely into 2022 – a good read through for both the market and sector.

Read more

31/08/2021 09:25

The healthcare sector will have varied influences

COVID has clearly provided a strong tailwind for vaccine producers overseas while pathology operators locally have seen a huge boost in demand which has flowed through to strong profits, Healius (HLS) and Sonic (SHL) are examples here.

Read more

30/08/2021 16:54

Healius (HLS) $4.68

FY21 Result: The result today were marginally lower than consensus expectations however the year on year growth was impressive all the same, a clear COVID beneficiary that is playing a key role in testing & pathology. The market looks forward and clearly the outlook for FY22 is for slower growth and it seemed like that was the focus today. Not a stock...

Read more

30/08/2021 09:03

Reporting Today (ALU, BKG, CWN, FMG, HLS, IVC, NXL, TPW, WGX)

Companies reporting today include: Adore Beauty (ABY), Altium (ALU), Crown Resorts (CWN), Fortescue (FMG), Healius (HLS), Invocare (IVC), Nuix (NXL), Temple & Webster (TPW)

Read more

16/03/2021 09:11

Healius (HLS) $4.02

Last month HLS delivered a solid report including a 190% increase in net profit and for the 1st 6-months of 2021 over $950m of revenue, up 16% year on year. Obviously the companies enjoyed a COVID generated surge in revenue through its pathology department but we believe some of this will be maintained as the world moves to a new norm post the pandemic.

Read more